



## REQUEST FOR QUOTATION no. 1/2026/M/STEP2.0

**Dated 28.05.2026 for CELON PHARMA SA with its registered office in Kielpin**

In connection with the implementation of the project no. 2024/ABM/08/00182 under the name "**Preclinical evaluation of the innovative 5-HT7 receptor agonist for the treatment of non-neuropathic pain**" as part of the Program: "**Competition for the development of R&D projects in the field of translational medicine – TRANSMED I**" co-financed by the **Medical Research Agency**.

Celon Pharma S.A. invites you to submit offers.

**DATE OF PUBLICATION: 28.05.2026**

**LOCATION: Kazuń Nowy**

**ANNOUNCEMENT PUBLICATION: obligatory**

**ORDERING PARTY:** Celon Pharma SA, ul. Ogrodowa 2a, 05-092 Kielpin

**OFFICIAL WEBSITE ADDRESS OF THE ORDERING PARTY**

**[www.celonpharma.com](http://www.celonpharma.com), telephone: 22 7515933**

**TYPE OF THE ORDERING PARTY: Private entity**

**A PARTIAL TENDER ALLOWED - NO**

**A VARIANT TENDER ALLOWED - NO**

**DATE OF COMPLETION OF THE CONTRACT: until 31<sup>th</sup> September 2026**

**PROCEDURE**

**Request for quotation**

### **CONTRACT AWARD PROCEDURE:**

1. This contract award procedure is not governed by the provisions of the Act of 11 September 2019 – the Public Procurement Law.
2. This contract award procedure shall be conducted with due observance of the principles of competitiveness, openness, transparency and equal access.
3. The Ordering Party reserves itself the right to nullify the procedure at any stage thereof without stating the reason.
4. The Ordering Party shall inform Suppliers about any changes made by publishing relevant information on its website.
5. The Ordering Party reserves itself the right to request additional information, documents or explanations.
6. In justified cases, at any time before the expiry of the deadline for the submission of tenders, Celon Pharma SA may modify or supplement the content of the invitation to tender.
7. This invitation to tender imposes no obligation on Celon Pharma SA to conclude a contract.

### **CELON PHARMA S.A.**

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów,  
tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: [info@celonpharma.com](mailto:info@celonpharma.com), [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.385.650 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061

**DETAILS CONCERNING THE OBJECT OF A CONTRACT:****CPV CODE: 73100000-3** – Research and experimental development services

| No. | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.  | <p><b>Conducting the following study on analgesic properties in various <i>in vivo</i> models, required for the implementation of the Project:</b></p> <p><b>1. Scope of research – <i>in vivo</i> models</b> - The subject of the order is the evaluation of the analgesic properties of the tested compound in at least 4 different, conducted in parallel <i>in vivo</i> pain models in the mouse species (<i>Mus musculus</i>). The models should encompass various mechanisms and types of pain and be validated using clinical reference compounds belonging to different pharmacological classes.</p> <p><b>2. Administration regimen and time points</b> The tested compound is administered as a single dose, via a route of administration selected by the Contractor and justified by the physicochemical or pharmacological properties of the drug candidate. The assessment of the analgesic response is conducted at a single time point following administration, selected by the Contractor on the basis of methodological knowledge of the compound's activity profile.</p> <p><b>3. Analysis of results</b> Results are expressed as percentage analgesic activity relative to the control group (% Activity vs. control animals).</p> <p><b>4. Documentation and final report</b> Preparation of complete documentation of the work performed, including final reports with analytical results, a description of the methodology applied, and source data.</p> |

**EQUIVALENT PRODUCTS**

1. Due to the continuation of research work as part of the said project, its specificity and unique nature, and the fact that reagents/materials used in the research process will have a significant impact on the shape of the conducted R&D work, for technical reasons of an objective nature, the description of the object of a contract indicates the reference number of the product(s).
2. Due to the uniqueness, unprecedented nature and precisely defined methodology of the conducted projects, research and experiments, as well as the necessity to maintain the continuity and repeatability of studies conducted by the Ordering Party, each Supplier offering products equivalent to the products described in the request for quotation shall be obliged:
  - to prove, on the basis of technical documentation/safety data sheets for reagents etc., and a written declaration, that the offered equivalent products (each of such products separately) meet the requirements allowing the continuation of research by the Purchaser with no need to perform additional activities (procedures), including, for example, calibration of devices or validation of the developed laboratory methods,

**CELON PHARMA S.A.**

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów,  
tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: [info@celonpharma.com](mailto:info@celonpharma.com), [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.385.650 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061



- to prove (by way of a written declaration included in the submitted tender) that the offered equivalent products will not cause any increase in costs due to the need to purchase additional products and other consumables,
- to assume liability – in the form of a written declaration – for any damage to equipment caused due to the use of the equivalent products offered and delivered, according to the opinion issued by an authorised repairer of the equipment manufacturer.

3. The Supplier shall pay contractual penalties to the Ordering Party:

- for any delay in the delivery of the object of a contract, for each started day of such delay, unless the delay is caused due to the Purchaser's fault,
- if the results of studies conducted with the use of the equivalent product do not satisfy the expectations,
- the Supplier expresses its consent to contractual penalties being deducted directly from the invoice amount at the time of payment of the VAT invoice related to the completion of the delivery.

**POINT SCORING SYSTEM:**

**TENDER EVALUATION CRITERIA:**

| Criterion | Weight [%] | Points | Evaluation formula                                                                     |
|-----------|------------|--------|----------------------------------------------------------------------------------------|
| Price     | 100%       | 100    | $C = \frac{\text{Lowest quoted price}}{\text{Quoted price}} \times 100 \text{ points}$ |

The total number of points that a particular tender receives will be calculated according to the formula below:

$$L = C$$

where:

- L – total number of points,
- C – points achieved in the "Price" criterion,

**Address and deadline for the submission of tenders:**

1. Tenders must be submitted to the Ordering Party to the address of its registered office: ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland, if sent by traditional or courier mail, or to the e-mail address: [przemyslaw.pietrasiuk@celonpharma.com](mailto:przemyslaw.pietrasiuk@celonpharma.com), if sent by electronic mail.
2. Tenders must be submitted on **08.06.2026** at the latest. If a tender is sent by traditional or courier mail, it shall be deemed submitted on the day of its delivery to the registered office of the Ordering Party.
3. Tenders submitted after the expiry of the deadline shall not be processed.
4. Tenders shall be evaluated at the registered office of the Ordering Party by **03.07.2026** at the latest.

**CELON PHARMA S.A.**

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów, tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: [info@celonpharma.com](mailto:info@celonpharma.com), [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.385.650 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061



5. The tenders submitted in a foreign currency will be converted at the average exchange rate of the National Bank of Poland (NBP) applicable on the date of drawing up the protocol of the request for tender.

#### Presentation of tenders:

1. Each Tenderer may submit only one tender. The tender must include the following details:
  - a. the number of the request for quotation,
  - b. the date of preparation,
  - c. the details of the Tenderer: address, telephone number, e-mail address, Tax Identification Number (NIP) (if available),
  - d. detailed information about the compliance of the proposed device with the specification,
  - e. **delivery time.**
2. The tender must be submitted along with the "Declaration of no personal or capital connections with the Ordering Party". Att. 1
3. The number of the request for quotation must also appear in the titles of e-mail messages, traditional or courier mail.
4. The tender must remain valid for at least 30 days after date of submission.
5. Each invoice should be have **30 days payment term (60 days preferred)**.
6. The tender preparation costs shall be borne by the Tenderer.
7. The tender must be initialled and signed by persons authorised to represent the Economic Operator/Supplier.

#### VII. NOTIFICATION OF THE CONTRACT AWARD

Information about the result of the contract award procedure shall be published on the Celon Pharma website

#### Please Note:

1. In connection with the entry into force of the Act of April 13, 2022 on special solutions in the field of counteracting aggression against Ukraine and serving the protection of national security (Journal of Laws, item 835), entities or citizens from the Russian Federation are excluded from participation in these proceedings, while subject to the sanctions specified in Art. 1 above of the Act, provided that on the day of submitting the offer they are on the list of persons and entities against which sanction measures should be applied, kept on the website of the Public Information Bulletin of the Minister of Internal Affairs and Administration,
2. The Contracting Party reserves the right to amend the agreement concluded with the awarded tenderer as a result of the procurement for the following reasons:
  - a) justified changes in the manner of performance of the subject-matter of the order,
  - b) objective reasons beyond the control of the Contracting Party or tenderer,
  - c) changes in legal regulations in force on the day of signing the contract,
  - d) force majeure,
  - e) occurrence of another obstacle, beyond the control of the tenderer, which prevents the performance of works,
  - f) in the event of changes to the Subject of the Agreement exceeding the material and/or financial scope indicated in the Tender, the Parties undertake that such changes will be introduced by way of an

#### CELON PHARMA S.A.

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów,  
tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: [info@celonpharma.com](mailto:info@celonpharma.com), [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.385.650 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061



amending Annex and according to the "Guidelines on the eligibility of expenditure under the European Regional Development Fund, the European Social Fund and the Cohesion Fund for 2014-2020".

3. Entities related to the Contracting Party either personally or by capital are excluded from participation in this procurement. Capital or personal relationships are understood as mutual relations between the Contracting Party or persons authorised to contract obligations on behalf of the Contracting Party or persons performing on behalf of the Contracting Party activities related to the conduct of the procedure for selecting a contractor and the contractor, consisting in particular of the following:
  - a) participation in a company as a partner in a civil law partnership or a partnership,
  - b) owning at least 10% of shares as long as the lower limit does not result from legal provisions or was not defined by IZ PO,
  - c) fulfilling the duties of member of the supervisory body or as manager, proxy or power of attorney,
  - d) being married, a direct family member, direct affinity, second-level relative or second degree affinity in lateral line or in relation to adoption, care or guardianship.
4. Each invoice issued should be due for at least 30 days.
5. Due to the necessity to maintain the continuity of tests, the Ordering Party provides for the possibility of submitting a supplementary order in the amount not exceeding 50% of the order value specified in the contract concluded with the Contractor.
6. The Ordering Party allows for the possibility of canceling the order or resigning from the order of goods and services included in the partial procedure or the entire procedure if funds are not obtained for the performance of this order or in other cases when the performance of the order will not be in the Ordering Party's best interest.
7. The Ordering Party admits the possibility of negotiating the presented offer.

**CELON PHARMA S.A.**

Biuro: ul. Ogrodowa 2A, 05-092 Łomianki / Kielpin, Dział R&D: ul. Marymoncka 15, 05-152 Kazuń Nowy / Czosnów,  
tel.: +48 22 751 59 33; fax: +48 22 751 74 77 e-mail: [info@celonpharma.com](mailto:info@celonpharma.com), [www.celonpharma.com](http://www.celonpharma.com)

**Organ rejestrowy:** Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

**Prezes Zarządu:** Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.385.650 PLN

**KRS:** 0000437778, **NIP :** 118 16 42 061